AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22182361
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Promotion (OHP) program implemented in nine schools since 2005
Trial: 11016021
Drug: Aspirin 320
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 320 mg
Trial: 18794027
Drug: Aspirin 0
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 0 mg
Trial: 12818934
Drug: Intrathecal opioid
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal opioid (1 micro g/kg sufentanil with 8 micro g/kg preservative-free morphine)
Trial: 8791955
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 1 g b.d.
Trial: 8791955
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. plus amoxycillin 1 g b.d.
Trial: 8791955
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg b.d. plus amoxycillin 1 g b.d.
Trial: 1536485
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g i.v. magnesium sulfate infused over 20 minutes
Trial: 6142700
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonist cimetidine in combination with H1 receptor antagonist chorpheniramine
Trial: 20732932
Drug: AP-D (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP-D (pemetrexed 500 mg/m² plus doxorubicin 60 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Trial: 20732932
Drug: AC-D (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC-D (doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² every 3 weeks followed by docetaxel 100 mg/m² every 3 weeks)
Trial: 19916712
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac sodium at a dose of 2 x 75 mg and additional breakthrough meperidine at 50 mg dosages if necessary
Trial: 19916712
Drug: Meperidine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 6 x 50 mg
Trial: 11052428
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid warmers (Group 3, n = 37)
Trial: 9261942
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (A/Yamagata/32/89, A/Beijing/352/89, B/Bangkok/163/90)
Trial: 9261942
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (A/Beijing/352/89)
Trial: 24385115
Drug: Clindamycin/tretinoin gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin/tretinoin gel patches
Trial: 24385115
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel patches
Trial: 24385115
Drug: Blank patches
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank patches (no gel)
Trial: 22428144
Drug: Lutein diacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein diacetate (20 mg/day)
Trial: 22428144
Drug: Crystalline lutein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline lutein (20 mg/day)
Trial: 18430173
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (Restylane, 1.4 mL)
Trial: 15888157
Drug: High-fluence laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fluence laser treatment
Trial: 15888157
Drug: Low-fluence laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluence laser treatment (Control)
Trial: 12552211
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine (ITB) 37.5 mg
Trial: 10532441
Drug: Verteporfin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verteporfin (6 mg per square meter of body surface area) administered via intravenous infusion of 30 mL over 10 minutes.
Trial: 10532441
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes.
Trial: 10532441
Drug: Verteporfin therapy
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin therapy for predominantly classic CNV lesions (area of classic CNV occupied 50% or more of the area of the entire lesion).
Trial: 10532441
Drug: Verteporfin treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verteporfin treatment.
Trial: 8828529
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (prednisone, median daily dose 20 mg, median duration 2 years)
Trial: 1795470
Drug: basic therapies
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basic therapies (nitrates + cardiac glycosides + diuretics)
Trial: 25063274
Drug: Glucagon treatment
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon treatment in isolated rat pancreatic islets
Trial: 25063274
Drug: Anti-insulin antibody
RxNorm normalized name: Anti-insulin antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-insulin antibody exposure in pancreatic islets
Trial: 25063274
Drug: Glucagon treatment
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon treatment in islets pretreated with diazoxide or anti-insulin antibody
Trial: 2446132
Drug: Immediate adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate adjuvant cisplatin‐based chemotherapy
Trial: 2446132
Drug: Observation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation with treatment at relapse
Trial: 11315838
Drug: Postprandial MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial MG and 3‐DG
Trial: 29960605
Drug: Tailored activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored activity counselling intervention (IG) encouraging to increase daily step count by 5%
Trial: 22367658
Drug: Fluvoxamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (50 mg/d for 7 days)
Trial: 22367658
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg/d for 7 days)
Trial: 22367658
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/d for 7 days)
Trial: 15608524
Drug: lopinavir/ritonavir (LPV/rtv)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir (LPV/rtv) 400/100 mg BID plus nevirapine (NVP) 200 mg BID (NVP group, n = 16)
Trial: 2401128
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion of felodipine (plasma concentration of 6 ng/ml after 20 minutes, sustained for 8 hours)
Trial: 2401128
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of felodipine (plasma concentration of 6 ng/ml after 8 hours)
Trial: 2401128
Drug: Control infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control infusions with saline and vehicle
Trial: 399250
Drug: Cefaclor (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (3 x 500 mg)
Trial: 399250
Drug: Amoxicillin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (3 x 750 mg)
Trial: 26395834
Drug: EU-RMP (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-RMP (5 mg/kg)
Trial: 26395834
Drug: US-RMP (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-RMP (5 mg/kg)
Trial: 21629997
Drug: Acute nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute nicotine (2 mg gum) in non-smokers
Trial: 9734742
Drug: Beta-carotene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (50 mg/d)
Trial: 3058132
Drug: Spironolactone (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100-200 mg/d)
Trial: 3058132
Drug: Potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate (50-200 mg/d)
Trial: 30342298
Drug: Pemafibrate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate (0.2 mg twice daily)
Trial: 18213545
Drug: Quercetin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (1000 mg/day for 3 weeks before, during, and 2 weeks after the race)
Trial: 10985706
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy and/or intra-aortic balloon counter-pulsation, coronary angiography, angioplasty and/or coronary artery bypass surgery
Trial: 10985706
Drug: Registry patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Registry patients managed with various treatments
Trial: 9173382
Drug: Coumarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumarin plus low-dose acetylsalicylic acid (125 mg/day)
Trial: 3993547
Drug: Atenolol (cardioselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (cardioselective beta-blocker)
Trial: 31556650
Drug: Trauma-focused cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive-behavioral treatments (TF-CBT)
Trial: 31556650
Drug: Present-Centered Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-Centered Therapy (comparison arm in 2 trials)
Trial: 23948637
Drug: Serotonin reuptake
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin reuptake inhibitors (SRI)
Trial: 19218250
Drug: Posterior sub-Tenon
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior sub-Tenon capsule injection of triamcinolone acetonide (PSTA) 20 mg
Trial: 14632810
Drug: Mycobacterium vaccae
RxNorm normalized name: Mycobacterium vaccae
DrugBank: Mycobacterium vaccae (DB18449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mycobacterium vaccae suspension
Trial: 14632810
Drug: Buffer solution
RxNorm normalized name: Buffer Solution, pH 5.00, Reference Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer solution (placebo)
Trial: 2065534
Drug: Intrapartum amnioinfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapartum amnioinfusion for replacement (IAR) with normal saline solution
Trial: 6627827
Drug: 5 gm
RxNorm normalized name: Olpruva 5 GM Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 gm activated charcoal every 2 hr for 6 doses
Trial: 6627827
Drug: 20 gm
RxNorm normalized name: HYQVIA 20 GM / 200 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 gm activated charcoal every 2 hr for 6 doses
Trial: 6627827
Drug: 40 gm
RxNorm normalized name: Gamunex 40 GM per 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 gm activated charcoal every 4 hr for 3 doses
Trial: 3909842
Drug: serum protein
RxNorm normalized name: Serum protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serum protein solution
Trial: 27521283
Drug: DADDS-G (Death
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DADDS-G (Death and Dying Distress Scale)
Trial: 9003465
Drug: Bestatin 90
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bestatin 90 and 180 mg daily for 60 days
Trial: 9003465
Drug: Bestatin 10
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bestatin 10 and 30 mg daily for 60 days
Trial: 6748872
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment (15 mg daily)
Trial: 26337246
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic Acid (TXA)
Trial: 27576483
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of etanercept and fumarates
Trial: 24447116
Drug: Low-intensity (LI)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity (LI) condition (monthly phone calls, printed materials, community referrals)
Trial: 19925875
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) plus high-dose corticosteroids
Trial: 18574157
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with paclitaxel plus cisplatin followed by the same chemotherapy with 50.4 Gy of radiation (arm B)
Trial: 12453928
Drug: i.m. bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. bupivacaine (5 mg ml(‐1)) 1 mg kg(‐1)
Trial: 12453928
Drug: i.m. lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. lidocaine (100 mg ml(‐1)) 2 mg kg(‐1)
Trial: 12453928
Drug: i.m. saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. saline 5 ml
Trial: 10703901
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2 l NaCl 0.9% over 2 h) during high salt (HS) diet
Trial: 10703901
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2 l NaCl 0.9% over 2 h) during low salt (LS) diet
Trial: 10703901
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2 l NaCl 0.9% over 2 h)
Trial: 1743373
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin cream (pretreated side)
Trial: 7072476
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg in 10 ml saline
Trial: 7072476
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml saline (control)
Trial: 7072476
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg in saline (if pain score exceeded 5)
Trial: 30991969
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly injectable formulation (AOM)
Trial: 14598513
Drug: Memantine (NMDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (NMDA receptor antagonist)
Trial: 18829205
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin aspart every 2 h until BG < 200 mg/dL
Trial: 18829205
Drug: Historical controls
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical controls with DM and an ED admission BG > 200 mg/dL
Trial: 19515731
Drug: Large bite
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large bite size (approximately 15 g)
Trial: 19515731
Drug: Small bite
RxNorm normalized name: PAD,BITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small bite size (approximately 5 g)
Trial: 17083378
Drug: 2-week therapy
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week therapy with omeprazole, amoxicillin, and clarithromycin
Trial: 17083378
Drug: 1-week therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-week therapy with omeprazole, amoxicillin, and clarithromycin
Trial: 22672578
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy (CT) alone
Trial: 29604186
Drug: Baminercept (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baminercept (100 mg subcutaneous injections every week for 24 weeks)
Trial: 27709863
Drug: Steroid (TA)
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (TA) injection
Trial: 27709863
Drug: Steroid (TA)
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (TA) injection (first)
Trial: 27709863
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) injection (first)
Trial: 27709863
Drug: Steroid (TA)
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (TA) first, Hyaluronic acid (HA) later
Trial: 27709863
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) first, Steroid (TA) later
Trial: 19340896
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (TCAs) including amitriptyline, imipramine, desipramine, doxepin, and trimipramine
Trial: 11300388
Drug: Epidural solution
RxNorm normalized name: Lidocaine Hydrochloride 1% Epidural Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural solution with fentanyl (SBAF)
Trial: 11300388
Drug: Epidural solution
RxNorm normalized name: Lidocaine Hydrochloride 1% Epidural Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural solution without fentanyl (SBA)
Trial: 11300388
Drug: Propofol anaesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anaesthesia and epidural solution without fentanyl (PBA)
Trial: 7890063
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of E2 and P
Trial: 342295
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate 0.1% cream
Trial: 342295
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate 0.1% ointment
Trial: 342295
Drug: Diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucortolone valerate 0.1% fatty ointment
Trial: 342295
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide 0.025% ointment
Trial: 31319510
Drug: Anserine/Carnosine Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anserine/Carnosine Supplementation (750 mg of anserine and 250 mg of carnosine per day)
Trial: 31319510
Drug: Anserine/Carnosine Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anserine/Carnosine Supplementation (750 mg of anserine and 250 mg of carnosine per day) in APOE4 (+) subjects
Trial: 28690011
Drug: Nintedanib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib maintenance treatment
Trial: 28690011
Drug: Placebo maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maintenance treatment
Trial: 23680226
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - 1 g intravenously as a bolus immediately after randomization, followed by continuous infusion of 1 g per 8 hours until aneurysm treatment or maximum of 24 hours.
Trial: 23680226
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without TXA.
Trial: 16925104
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment of mild anemia with erythropoietic therapy
Trial: 16925104
Drug: Erythropoietic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietic therapy
Trial: 12958322
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole 400 mg/d
Trial: 12958322
Drug: Aspirin 30
RxNorm normalized name: aspirin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 30 to 325 mg/d
Trial: 7514030
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) (Filgrastim) at a dose of 5 micrograms/kg/day i.m. from day 6 to day 19
Trial: 7514030
Drug: Mitoxantrone (DHAD)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (DHAD) 12 mg m-2 i.v. on day 1; Ifosfamide (IFO) 4 g m-2 i.v. on days 1 and 2; Mesna 800 mg m-2 i.v. t.i.d. on days 1 and 2